"Is It Time to Change Clinical Trial Inclusion Criteria in Lung Cancer?" - John Schieszer
It may be possible to double the number of patients eligible for clinical trials for advanced non-small-cell lung cancer (NSCLC). A study found that the use of expanded clinical trial inclusion criteria would nearly double the percentage of patients eligible to enroll in clinical trials. These results were presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The expanded clinical trial eligibility criteria would allow advanced NSCLC patients with brain metastases and with limited kidney function to enroll in clinical trials. Nicholas Rohs, MD, an assistant professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai, said that this is an important study highlighting a reasonable way to improve clinical trial engagement and enrollment, which ultimately leads to better care and outcomes for patients.
— Nicholas Rohs, MD, Assistant Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai ,The Tisch Cancer Institute, Mount Sinai Health System